Hangzhou Tigermed Consulting Co., Ltd. Class A
38.00
HKD
-3.14
(-7.63%)
ISIN
CNE1000040M1
Return %
Stock
S&P 500
1Y
-9.57
14.20
3Y
-5.59
81.12
5Y
-74.75
68.34
Capital Structure
CNY
•
in mil. unless spec.Working Capital
CNY
•
in mil. unless spec.Growth Rates
CNY
•
in mil. unless spec.Quarterly Revenue
CNY
•
in mil. unless spec.Quarterly Earnings Per Share
CNY
•
in mil. unless spec.Quarterly Dividends Per Share
CNY
•
in mil. unless spec.Company Description
- CEO
- Zeng Yu Wen
- Full Time Employees
- 11,130
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- No. 508, Lujiatan Street Hangzhou TJ China 310051
- IPO Date
- Aug 17, 2012
- Website
- tigermed.net
- Similar Companies
- Business
- Hangzhou Tigermed Consulting Co., Ltd. is a leading contract research organization (CRO) specializing in comprehensive clinical research services for the pharmaceutical, biotechnology, and medical device industries. Founded in 2004 and headquartered in Hangzhou, China, the company offers a wide range of core services including technical support for Phase I to Phase IV clinical trials; clinical trial management; data management and biostatistics; regulatory affairs consultancy; pharmacovigilance; site management and monitoring; and medical writing. Tigermed’s service portfolio spans preclinical research such as medicinal chemistry, compound screening, drug metabolism, pharmacokinetics, safety and toxicology, bioanalytical services, and formulation research and development. The company operates globally with significant presence across Asia, the United States, Europe, and other regions through subsidiaries and strategic partnerships. In recent developments, Tigermed has made strategic investments and expansions to reinforce its market-leading position. In the first half of 2024, Tigermed acquired the China division of NAMSA, a renowned medical device CRO, and entered into an exclusive strategic cooperation agreement with NAMSA for China and global collaboration. The company notably expanded its pharmacovigilance team by establishing a local unit in the U.S., signed more than 80 new projects, and gained over 100 new clients, reflecting rapid growth in this regulatory compliance segment. Tigermed also facilitated the approval of multiple new drugs and innovative medical devices in China, the U.S., and Japan, supporting over 2,000 ongoing site management projects and nearly 1,000 data management and statistical analysis projects as of mid-2024. Additionally, the launch of a Solutions Business Unit aims to provide integrated, one-stop services for multinational corporations (MNCs) on China projects, while Tigermed accelerates its investments and brand-building efforts in key overseas markets such as the U.S., Australia, and Europe. The company’s significant collaborations and partnership-driven approach underpin its geographical and service expansion, covering more than 30 countries. Tigermed leverages advanced technology platforms, including AI-driven data analytics, to enhance clinical trial efficiency and quality. It supports extensive therapeutic areas including oncology, cardiovascular, infectious diseases, respiratory, hematology, orthopedics, and vaccines. Tigermed’s client base includes global pharmaceutical, biotech, and medical device companies seeking reliable, regulatory-compliant clinical development support. The firm emphasizes operational excellence, innovation, and ethical compliance, which has led to a strong market share in China’s clinical CRO sector and steady growth internationally. Hangzhou Tigermed Consulting Co., Ltd. remains focused on advancing drug and device development through integrated R&D service platforms, facilitating faster regulatory approval processes, and expanding its service breadth from clinical trial management to post-marketing pharmacovigilance and regulatory consulting. Its forward-looking strategy emphasizes expanding global presence, enhancing technology adoption, and sustaining collaborative ties with multinational industry leaders to improve patient outcomes worldwide. This approach has driven Tigermed’s robust financial performance, with notable revenue growth, increased profitability, and ongoing investments in R&D to sustain leadership in the fast-evolving clinical research industry.